Leo Pharma As patents expiration
1. Desonate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6387383 | LEO PHARMA AS | Topical low-viscosity gel composition |
Aug, 2020
(3 years ago) | |
Drugs and Companies using DESONIDE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: Desonate gel is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older
Dosage: GEL;TOPICAL
DESONATE family patents
2. Dovonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39706 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| US5763426 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
Drugs and Companies using CALCIPOTRIENE ingredient
Market Authorisation Date: 22 July, 1996
Treatment: NA
Dosage: CREAM;TOPICAL
DOVONEX family patents
3. Enstilar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| US10716799 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US9119781 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10130640 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10617698 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10688108 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10682364 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10660908 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US9566286 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
|
US10130640 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(7 years from now) | |
|
US9119781 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 30, 2023 |
| New Patient Population(NPP) | Jul 30, 2022 |
| New Product(NP) | Oct 16, 2018 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 16 October, 2015
Treatment: Plaque psoriasis; Topical treatment of plaque psoriasis in patients 12 years and older
Dosage: AEROSOL, FOAM;TOPICAL
ENSTILAR family patents
4. Finacea patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6534070 | LEO PHARMA AS | Composition with azelaic acid |
Nov, 2018
(5 years ago) | |
| US6730288 | LEO PHARMA AS | Mousse composition |
Sep, 2019
(4 years ago) | |
| US8900554 | LEO PHARMA AS | Foamable composition and uses thereof |
Oct, 2023
(6 months ago) | |
| US10322085 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Oct, 2023
(6 months ago) | |
| US8722021 | LEO PHARMA AS | Foamable carriers |
Oct, 2023
(6 months ago) | |
| US8435498 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Mar, 2024
(a month ago) | |
| US7700076 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Sep, 2027
(3 years from now) | |
| US10117812 | LEO PHARMA AS | Foamable composition combining a polar solvent and a hydrophobic carrier |
Oct, 2027
(3 years from now) | |
| US9265725 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Dec, 2027
(3 years from now) | |
| US9211259 | LEO PHARMA AS | Antibiotic kit and composition and uses thereof |
Feb, 2029
(4 years from now) | |
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 24 December, 2002
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM;TOPICAL
FINACEA family patents
5. Protopic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5665727 | LEO PHARMA AS | Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them |
Sep, 2014
(9 years ago) | |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 08 December, 2000
Treatment: For the treatment of dermatitis
Dosage: OINTMENT;TOPICAL
PROTOPIC family patents
6. Taclonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5763426 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| USRE39706 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| US6787529 | LEO PHARMA AS | Topical composition |
Jan, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 23, 2017 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 09 January, 2006
Treatment: Psoriasis; Treatment of moderate plaque psoriasis
Dosage: SUSPENSION;TOPICAL
TACLONEX family patents
7. Taclonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6787529 | LEO PHARMA AS | Topical composition |
Jan, 2020
(4 years ago) | |
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 25, 2022 |
| Pediatric Exclusivity(PED) | Jan 25, 2023 |
| New Indication(I-659) | Oct 17, 2015 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: Plaque psoriasis
Dosage: SUSPENSION;TOPICAL
TACLONEX family patents